Pharmacological activation of the GR is a proven, effective treatment strategy for lymphoid cancers, including acute lymphoblastic leukaemia, chronic lymphocytic leukaemia and multiple myeloma41. Here, NR3C1 is linked to acute lymphoblastic leukemia.